Relationship of Test Positivity Rates with COVID-19 Epidemic Dynamics.

COVID-19 SARS-CoV-2 effective reproduction number epidemics laboratory diagnosis outbreaks pandemic surveillance

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
27 04 2021
Historique:
received: 07 04 2021
revised: 23 04 2021
accepted: 24 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 6 5 2021
Statut: epublish

Résumé

Detection and isolation of infected people are believed to play an important role in the control of the COVID-19 pandemic. Some countries conduct large-scale screenings for testing, whereas others test mainly people with high prior probability of infection such as showing severe symptoms and/or having an epidemiological link with a known or suspected case or cluster of cases. However, what a good testing strategy is and whether the difference in testing strategy shows a meaningful, measurable impact on the COVID-19 epidemic remain unknown. Here, we showed that patterns of association between effective reproduction number (Rt) and test positivity rate can illuminate differences in testing situation among different areas, using global and local data from Japan. This association can also evaluate the adequacy of current testing systems and what information is captured in COVID-19 surveillance. The differences in testing systems alone cannot predict the results of epidemic containment efforts. Furthermore, monitoring test positivity rates and severe case proportions among the nonelderly can predict imminent case count increases. Monitoring test positivity rates in conjunction with the concurrent Rt could be useful to assess and strengthen public health management and testing systems and deepen understanding of COVID-19 epidemic dynamics.

Identifiants

pubmed: 33925665
pii: ijerph18094655
doi: 10.3390/ijerph18094655
pmc: PMC8125747
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 16809810

Références

Nat Biotechnol. 2020 Aug;38(8):932-933
pubmed: 32704170
Nature. 2021 Jan;589(7840):82-87
pubmed: 33171481
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Jpn J Infect Dis. 2020 Nov 24;73(6):491-493
pubmed: 32611985
Nat Biotechnol. 2020 Jun;38(6):653
pubmed: 32493981
Nat Med. 2021 Feb;27(2):183
pubmed: 33542537
Lancet. 2021 Apr 3;397(10281):1265-1275
pubmed: 33773118
JAMA Intern Med. 2021 Jul 1;181(7):913-921
pubmed: 33821922
Science. 2020 Jul 24;369(6502):413-422
pubmed: 32532802
Lancet Infect Dis. 2020 Oct;20(10):1105-1106
pubmed: 32559453
BMJ. 2020 Aug 20;370:m3262
pubmed: 32819920
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437
Science. 2021 Feb 19;371(6531):
pubmed: 33323424
Nat Hum Behav. 2020 Sep;4(9):964-971
pubmed: 32759985
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:157-161
pubmed: 32869006
Nat Commun. 2020 Nov 20;11(1):5917
pubmed: 33219229
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Nat Immunol. 2021 Mar;22(3):262-263
pubmed: 33627881
J Epidemiol. 2021 Jun 5;31(6):387-391
pubmed: 33814508
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
Chaos Solitons Fractals. 2020 Oct;139:110059
pubmed: 32834612
Science. 2021 Jul 16;373(6552):
pubmed: 34083451
Cell Host Microbe. 2021 Apr 14;29(4):503-507
pubmed: 33676588
Nature. 2020 Jul;583(7816):346-348
pubmed: 32620883
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32521222
BMJ. 2020 Nov 3;371:m4268
pubmed: 33144291
Lancet Infect Dis. 2021 Jun;21(6):793-802
pubmed: 33743847
Science. 2020 Aug 7;369(6504):624-626
pubmed: 32764055
Lancet Microbe. 2020 Jul;1(3):e103-e104
pubmed: 32835338

Auteurs

Yuki Furuse (Y)

Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8501, Japan.

Yura K Ko (YK)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Kota Ninomiya (K)

National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
National Institute of Public Health, Wako 351-0197, Japan.

Motoi Suzuki (M)

National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Hitoshi Oshitani (H)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH